A/Prof Alexander van Akkooi
A/Prof van Akkooi has received honoraria from Amgen, Bristol-Myers Squibb, Novartis, Merck-Pfizer, MSD Merck, Pierre Fabre, Provectus, Sanofi, Sirius Medical and 4SC, and receives research funding from Amgen and Merck-Pfizer.
Dr Iris Bartula
Dr Iris Bartula has no interests to declare.
Rebecca Biviano
Rebecca Biviano has no interests to declare.
A/Prof Matteo Carlino
A/Prof Carlino has acted as a consultant advisor for the following companies: Bristol-Myers Squibb, MSD, Novartis, Amgen, Roche, Pierre Fabre, Provectus, Ideaya, Sanofi, Merck Serono, Nektar and Eisai. He has also received honoraria from Bristol-Myers Squibb, Merck Sharpe Dohme and Novartis.
A/Prof Sydney Ch’ng
A/Prof Sydney Ch’ng has no interests to declare.
Shahn Coburn
Shahn Coburn has no interests to declare.
Prof Diona Damian
Prof Diona Damian has no interests to declare.
Michelle Davey
Michelle Davey has no interests to declare.
Danielle Fischer
Danielle has acted as an advisor to Novartis.
Dr Bruna Gouveia
Dr Gouveia has no interests to declare
Prof Pascale Guitera
Prof Guitera has acted as a consultant advisor and received honorarium from the following companies: Metaoptima and Avene.
Prof Angela Hong
Prof Hong is an author for UptoDate and receives loyalty from the publication.
Prof Georgina Long AO
Prof Long is a consultant advisor for Agenus Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Evaxion Biotech A/S, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Innovent Biologics USA Inc, Merck Sharpe & Dohme (Australia) Pty Limited, Novartis Pharma AG, OncoSec Medical Australia, PHMR Limited, Pierre Fabre, Provectus Australia, Qbiotics Group Limited and Regeneron Pharmaceuticals Inc.
Dr Nigel Maher
Dr Nigel Maher has no interests to declare.
Dr Linda Martin
Dr Martin has acted as a consultant with Bristol-Myers Squibb.
A/Prof Alexander Menzies
A/Prof Alexander Menzies has acted as a consultant advisor and received honorarium from the following companies: QBiotics, Bristol-Myers Squibb, MSD, Novartis, Roche and Pierre-Fabre.
Dr Niamh-Anna O’Sullivan
Dr Niamh-Anna O’Sullivan has no interests to declare.
Dr Thomas Pennington
Dr Pennington has no interests to declare.
Dr Alison Potter
Dr Alison Potter has no interests to declare.
Dr Adrian Quek
Dr Adrian Quek has no interests to declare.
Jodi Ratnik
Jodi Ratnik has no interests to declare.
Dr Robert Rawson
Dr Robert Rawson has no interests to declare.
Dr Michael Rtshiladze
Dr Michael Rtshiladze has no interests to declare.
A/Prof Robyn Saw
A/Prof Robyn Saw is on the advisory board for QBiotics, Novartis and MSD, and has received speaking honoraria from Bristol-Myers Squibb and Novartis.
Prof Richard Scolyer
Prof Richard Scolyer has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics and GlaxoSmithKline.
Dr Kerwin Shannon
Dr Kerwin Shannon has no interests to declare.
Dr Ines Silva
Dr Silva has received speaking honoraria from MSD.
Dr Bringha Shivalingam
Dr Bringha Shivalingam has no interests to declare.
Dr Annika Smith
Dr Annika Smith has no interests to declare.
Prof Andrew Spillane
Prof Spillane has no interests to declare.
A/Prof Jonathan Stretch AM
A/Prof Jonathan Stretch AM has no interests to declare.
Prof John Thompson AO
Professor Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, travel support from GSK and Provectus Inc, and support for conference attendance from Novartis.
A/Prof Alex Varey
A/Prof Varey has received honoraria from Medtronic, Acelity and Synthes.
Denise Wilson
Denise Wilson has no interests to declare.
3 Comments
Useful to listen to.
I do have a few gripes though – GPs listening to this podcast are likely to be very experienced, likely Fellowed i.e. Specialists in their own right, and advising them in detail how to treat hypothyroidism, rashes or diarrhoea, is rather patronising.
I also found it a bit frustrating to be told repeatedly that any queries that I may have about my patient’s treatment should be addressed to the Clinical Nurse Consultant. With the greatest of respect to the Nurse’s skills there are times when I, as a Primary Care Specialist, need to talk to the Oncology Specialist. This was never mentioned as a primary option. Both of us are very busy and if I interrupt my busy day to spend the time on the phone seeking advice it would seem reasonable to expect the Oncologist to be willing to do the same.
Very nice podcast, full of helpful information for clinical practice